StockMarketWire.com - Biotechnology company ValiRx said the first article containing results from a clinical trial of its cancer therapy had been accepted for publication by a key journal.

The peer-reviewed article on the treatment, VAL401, would appear in the European Journal of Drug Metabolism and Pharmacokinetics early in 2019.

VAL401 was a new formulation of the anti-psychotic drug, risperidone, enabling the company's oncology treatment.

This analysis considered the clinical significance of the VAL401 results in comparison to previously reported data for conventional risperidone, providing a theoretical insight into the altered activity of the therapeutic.

'Peer-reviewed publications are always interesting to complete, as the article is very much shaped and expanded by the anonymous expert reviewers, providing a respected validation of the data,' chief executive Suzy Dilly said.


At 8:17am: [LON:VAL] ValiRx PLC share price was +0.03p at 1.13p



Story provided by StockMarketWire.com